Comparison of Seropositivity to Trichomonas vaginalis between Men with Prostatic Tumor and Normal Men
- Author:
Jung Hyun KIM
1
;
Hong Sang MOON
;
Kyu Shik KIM
;
Hwan Sik HWANG
;
Jae Sook RYU
;
Sung Yul PARK
Author Information
- Publication Type:Brief Communication
- Keywords: Trichomonas vaginalis; seropositivity; benign prostatic hyperplasia; prostate cancer
- MeSH: Enzyme-Linked Immunosorbent Assay; Health Promotion; Humans; Inflammation; Korea; Male; Outpatients; Passive Cutaneous Anaphylaxis; Prostate; Prostatic Diseases; Prostatic Hyperplasia; Prostatic Neoplasms; Seroepidemiologic Studies; Trichomonas vaginalis; Trichomonas
- From:The Korean Journal of Parasitology 2019;57(1):21-25
- CountryRepublic of Korea
- Language:English
- Abstract: Trichomoniasis is the most common curable sexually-transmitted infection. Most Trichomonas vaginalis-infected men are asymptomatic and can remain undiagnosed and untreated, and this has been thought to result in chronic persistent prostatic infection. Chronic inflammation is regarded as the major factor in the pathogenesis and progression of benign prostatic hyperplasia (BPH) and prostatic cancer (PCa). The aim of this study is to identify seropositivity to T. vaginalis in men with prostate tumors (BPH or PCa) visited to Hanyang University Hospital. A total of 183 men were enrolled between October 2013 and November 2014. They consisted of 139 with BPH (mean age: 64.0±0.07) and 44 with prostate cancer (mean age: 73.3±0.18). We carried out ELISA to identify the seropositivity to T. vaginalis. Mixed lysate antigen extracted from 8 strains of T. vaginalis was used in the ELISA. Also 58 male outpatients visited to Health Promotion Center in Hanyang University Hospital were evaluated for comparing group. As a results, seropositivity to T. vaginalis in patients with prostatic diseases was 19.7% (BPH: 18.7%, PCa: 22.7%) and it was significantly higher than the 1.7% of the comparing healthy group (P=0.001). Therefore, prostatic tumor showed higher seropositivity against T. vaginalis than normal men. As far as we know, this is the first report about seroprevalence in prostatic tumor in Korea.
